IVF Protocols and Medications: How Doctors Choose a Plan
Key Takeaways
IVF protocols are personalised treatment plans designed to recruit eggs safely and time retrieval accurately, not one-size-fits-all drug schedules. The main choices involve how to stimulate the ovaries, how to prevent premature ovulation, and how to minimise OHSS risk without compromising cumulative success. The right protocol balances your diagnosis, ovarian reserve, and previous response.
Key evidence: ESHRE — Ovarian stimulation for IVF/ICSI guideline (2020) Alexander et al. — Random vs conventional start stimulation (2021) Massin et al. — DuoStim in poor ovarian responders (BISTIM RCT, 2023)
When patients receive their IVF medication calendar, the list of daily injections, nasal sprays, and tablets can feel daunting. It is natural to focus on the names and dosages of the drugs. But in fertility medicine, the underlying clinical logic matters far more than the brand on the box.
An IVF protocol is a carefully tailored medical strategy. The same hormone medication can be used very differently depending on your age, antral follicle count, anti-Müllerian hormone (AMH) level, previous response, and specific diagnosis such as polycystic ovary syndrome (PCOS) or endometriosis.
Understanding how your fertility specialist selects and adjusts this plan helps replace cycle anxiety with informed confidence.
What an IVF protocol is designed to achieve
Short answer: An IVF protocol aims to mature a predictable, useful cohort of eggs safely while preventing premature ovulation and avoiding dangerous ovarian hyperstimulation.
Stimulation is not a contest to produce the maximum possible number of eggs. Chasing excessive numbers can increase the risk of ovarian hyperstimulation syndrome (OHSS) without necessarily improving the outcome that matters to you. A well-designed protocol balances several competing priorities:
- recruiting an optimal cohort of follicles tailored to your ovarian reserve
- preventing an untimely luteinizing hormone (LH) surge before the eggs are ready
- minimising OHSS risk, especially in high responders and patients with PCOS
- adapting flexibly if follicles grow faster or slower than expected
- aligning with the planned transfer strategy, whether fresh embryo transfer or freeze-all
As highlighted in the ESHRE guideline on ovarian stimulation for IVF/ICSI, individualising the starting dose and protocol based on ovarian reserve biomarkers remains the cornerstone of safe, effective treatment.
Common IVF stimulation protocols
Different protocols control the timing of follicle recruitment and prevent premature ovulation through distinct hormonal mechanisms.
1. The GnRH antagonist protocol (a common modern first-line choice)
Short answer: The antagonist protocol is widely used because it is relatively short and allows a GnRH agonist trigger, often with freeze-all when OHSS risk is high, to substantially reduce the risk of moderate-to-severe OHSS.
In this protocol, gonadotropin stimulation begins on day 2 or 3 of your menstrual cycle. Once the leading follicles reach approximately 12 to 14 mm (or around day 5 to 6 of stimulation), a gonadotropin-releasing hormone (GnRH) antagonist is added daily. The antagonist acts immediately to block the pituitary gland from releasing an LH surge.
This protocol offers major advantages:
- fewer injection days (typically 9 to 11 days total)
- reduced total gonadotropin dose compared to long protocols
- the ability to use a GnRH agonist trigger instead of hCG when the response suggests a higher OHSS risk; a freeze-all plan may further reduce that risk
Because of this flexibility, guidelines particularly favour antagonist-based stimulation when OHSS risk is a concern, including in patients with polycystic ovary syndrome. The final choice still depends on the full clinical picture.
2. The long GnRH agonist protocol
Short answer: The long agonist protocol achieves deep pituitary suppression before stimulation begins, offering precise scheduling and benefits in selected cases of endometriosis.
In a long protocol, a GnRH agonist is started in the luteal phase of the preceding cycle (around day 21) or following oral contraceptive pretreatment. It initially causes a transient flare of hormones before fully suppressing pituitary gonadotropin secretion over 10 to 14 days. Once suppression is confirmed, gonadotropin stimulation starts while the agonist continues at a lower maintenance dose.
While highly predictable for clinic scheduling, this approach requires several weeks of daily medication, increases the overall drug requirement, and prevents the use of an agonist trigger if hyperstimulation threatens. Today, clinicians reserve it primarily for selected patients with severe endometriosis or adenomyosis, or those with recurrent premature LH surges.
3. Progestin-primed ovarian stimulation (PPOS)
Short answer: PPOS uses oral progestin tablets instead of injectable antagonists to prevent premature ovulation, requiring embryo freezing for a later cycle.
In PPOS, oral progestins (such as medroxyprogesterone acetate or micronized progesterone) are taken daily from the start of stimulation alongside gonadotropins. The progestin reliably blocks the LH surge through central hypothalamic-pituitary feedback.
Because continuous progestin exposure alters endometrial development, fresh embryo transfer cannot be performed in the same cycle. A systematic review and meta-analysis by Cui et al. on progestin-primed ovarian stimulation reported broadly comparable laboratory and pregnancy outcomes with conventional antagonist cycles in the settings studied. PPOS may be considered when a freeze-all plan is already appropriate, including some donor and fertility-preservation cycles.
4. DuoStim (dual stimulation in one cycle)
Short answer: DuoStim involves two consecutive stimulation and egg retrieval cycles within a single menstrual month to maximize egg yield in poor responders.
Follicles develop in continuous waves throughout the menstrual cycle rather than in a single monthly cohort. DuoStim takes advantage of this biology by performing a first stimulation during the follicular phase, followed by a second stimulation starting 2 to 5 days after the first egg collection during the luteal phase.
In the multicentre BISTIM randomised controlled trial by Massin et al., DuoStim produced more embryos within the study period, but it did not significantly shorten the time to a clinical pregnancy. Because the luteal-phase stimulation is not designed for an immediate transfer, embryos are frozen for a later frozen embryo transfer. DuoStim is not a routine first-line tool for standard patients; it is a specialised strategy that may be discussed when embryo accumulation time matters, particularly in selected patients with low ovarian reserve.
5. Random-start stimulation
Short answer: Random-start stimulation allows egg retrieval cycles to begin immediately on any cycle day for urgent medical fertility preservation.
When a patient receives a cancer diagnosis requiring urgent chemotherapy or pelvic radiation, delaying treatment until the next menstrual period is often impossible. As demonstrated in the systematic review by Alexander et al. on random-start ovarian stimulation, starting stimulation during the luteal or late follicular phase yields comparable mature oocyte numbers and fertilisation rates to conventional start cycles without delaying oncology care.
Core medication groups in IVF
Understanding what each prescription does helps simplify your daily routine.
Gonadotropins (follicle stimulants)
These medications provide follicle-stimulating hormone (FSH), sometimes combined with luteinizing hormone (LH) activity, to encourage multiple follicles to grow simultaneously:
- Recombinant FSH (rFSH): Pure FSH produced through recombinant DNA technology.
- Human menopausal gonadotropin (hMG): Purified gonadotropins containing an equal 1:1 balance of FSH and LH activity.
- Long-acting FSH: A modified molecule providing sustained stimulation over several days with a single injection.
Ovulation blockers (preventing premature LH surge)
These drugs prevent your body from releasing eggs prematurely before the scheduled retrieval:
- GnRH antagonists: Rapidly bind and block GnRH receptors within hours.
- GnRH agonists: Initially stimulate then desensitize receptors when given over extended periods.
- Oral progestins: Provide central feedback suppression during PPOS cycles.
Trigger medications (final oocyte maturation)
The trigger injection completes the final maturation process, and egg retrieval is usually scheduled about 34 to 36 hours later:
- Recombinant hCG or urinary hCG: Mimics the natural LH surge; a common option when a fresh transfer is planned and OHSS risk is low.
- GnRH agonist trigger: Triggers a short, self-limiting endogenous LH surge; a key OHSS-risk reduction option in antagonist cycles.
- Dual trigger: Combines a GnRH agonist with a small dose of hCG to improve mature egg yield in selected poor-yield cycles.
Luteal phase support
Progesterone support is commonly prescribed after egg retrieval because stimulation and retrieval can affect luteal-phase hormone production. The exact plan depends on the type of cycle and transfer:
- Progesterone: Administered vaginally, subcutaneously, or intramuscularly to prepare and maintain the receptive endometrium.
- Estrogen: Added in selected frozen embryo transfer protocols or programmed cycles.
Because stimulation medications and luteal support are frequently itemised separately from clinic procedure packages, reviewing how IVF treatment costs are structured helps avoid unexpected expenses.
Why medication doses change mid-cycle
Short answer: Dose titration during ultrasound monitoring is a sign of responsive clinical management, not a complication.
Ovarian response to gonadotropins varies from one patient to another. During your cycle, regular transvaginal ultrasounds track follicle growth while blood tests monitor serum oestradiol and progesterone levels. If follicles develop faster or slower than anticipated, your doctor will adjust the daily dose.
Common clinical adjustments include:
- increasing the gonadotropin dose if initial recruitment is slower than expected
- reducing the dose if oestradiol levels rise too steeply
- adjusting the exact start day of the antagonist injection
- converting from an hCG trigger to an agonist trigger with freeze-all to protect you from OHSS
To explore the clinical mechanisms behind these adjustments, see our guide on ovarian stimulation in IVF.
Dr. Aksoy’s clinical perspective
Dr. Aksoy’s Approach: Dr. Aksoy does not regard one IVF protocol as universally “best”. His clinical framework starts with ovarian reserve, the previous response, the diagnosis and the safety profile of the current cycle. Antagonist protocols are often the practical starting point because they allow flexible OHSS-reduction strategies, while long agonist protocols, PPOS and DuoStim are reserved for clearly defined situations. More medication does not automatically mean a better outcome; careful monitoring and proportionate adjustment matter more.
Questions to discuss with your fertility specialist
- Which stimulation protocol are you recommending for my ovarian reserve, and why?
- What is my estimated risk for ovarian hyperstimulation syndrome?
- Is our baseline strategy a fresh embryo transfer or a planned freeze-all?
- What specific criteria will guide any medication dose changes during monitoring?
- If I had a poor or suboptimal response in a previous cycle, how does this new protocol address that?
To learn more about optimising your treatment parameters, review our evidence-based strategies to improve IVF success and key IVF treatment risks and considerations.
FAQ
How is the IVF protocol chosen?
Your specialist chooses a protocol based on your age, antral follicle count (AFC), anti-Müllerian hormone (AMH) level, body mass index, specific diagnosis (such as PCOS or endometriosis), previous stimulation history, and whether a fresh transfer or freeze-all is planned.
Why is the GnRH antagonist protocol widely used?
The antagonist protocol is generally shorter and requires fewer injections than a long agonist protocol. Comparative evidence has found similar live-birth outcomes overall, while the antagonist design makes it easier to use an agonist trigger and, when appropriate, a freeze-all plan to reduce OHSS risk.
Is a medication dose adjustment during monitoring a bad sign?
No. Dose adjustments are a routine part of attentive cycle monitoring. Adjusting gonadotropin units in response to ultrasound follicle measurements and oestradiol levels helps tailor follicle recruitment while keeping safety in view.
When is DuoStim considered?
DuoStim is reserved for women with low ovarian reserve (poor ovarian responders) or patients facing urgent gonadotoxic treatments who need to accumulate eggs or embryos quickly within a single menstrual cycle. All resulting embryos must be frozen.
What is the difference between an hCG trigger and an agonist trigger?
An hCG trigger mimics the LH surge and has a longer luteotrophic effect, which can be useful when a fresh transfer is planned. In an antagonist cycle, a GnRH agonist trigger releases a shorter LH surge and can markedly reduce OHSS risk, especially when combined with a freeze-all strategy. If a fresh transfer follows an agonist trigger, additional luteal support is needed.
Sources
- The ESHRE Guideline Group on Ovarian Stimulation, Bosch E, Broer S, Griesinger G, et al. “ESHRE guideline: ovarian stimulation for IVF/ICSI.” Human Reproduction Open, 2020(2):hoaa009. PubMed
- Alexander VM, Hopkins MK, Tremont K, et al. “Ovarian stimulation for fertility preservation in women with cancer: A systematic review and meta-analysis comparing random and conventional starts.” Human Reproduction Update, 2021;27(3):477-493. PubMed
- Massin N, Bry-Gauillard H, Kerbrat V, et al. “The BISTIM study: a randomized controlled trial comparing dual ovarian stimulation (duostim) with two conventional ovarian stimulations in poor ovarian responders undergoing IVF.” Human Reproduction, 2023;38(4):641-653. PubMed
- Cui L, Lin Y, Wang F, et al. “Effectiveness of progesterone-primed ovarian stimulation in assisted reproductive technology: a systematic review and meta-analysis.” Archives of Gynecology and Obstetrics, 2021;303(3):615-630. PubMed
- Devroey P, Polyzos NP, Blockeel C. “An OHSS-Free Clinic by prevention of OHSS with a GnRH-agonist trigger.” Human Reproduction, 2011;26(10):2593-2597. PubMed
- American Society for Reproductive Medicine. “Prevention of moderate and severe ovarian hyperstimulation syndrome: a guideline.” 2023. ASRM
Add as a Preferred Source on Google
You can add draksoyivf.com as one of your preferred health information sources on Google.
The content has been created by Dr. Senai Aksoy and medically approved.